Zenas BioPharma, Inc.(ZBIO)

$29.51—

Chart

Zenas BioPharma, Inc.(ZBIO)

NASDAQ

$29.51—

Chart Studio

ZBIO(ZBIO)

ZBIO

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-1.23

Nov 12, 2026 · Reports before open

Revenue Estimate

$1M

Analyst Sentiment

Wall St. Consensus

Buy

5 analysts·Limited coverage

Score

4 Buy (80%)1 Hold (20%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

480%

Hold

120%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$32.00

+8.4%

Consensus

$32.00

+8.4%

Bull

$32.00

+8.4%

12-Month Target Range5 analysts

$32.00$32.00$32.00

Current $29.51Consensus

Current Price

$29.51

Upside to Consensus

$2.49

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+111.00%

EPS—

FY2028

Rev+108.77%

EPS—

FY2029

Rev+139.46%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$30M	$64M	$133M	$319M	$524M
Low	$24M	$22M	$30M	$122M	$201M
High	$36M	$91M	$380M	$606M	$997M
EBITDA Avg	$-12M	$-25M	$-51M	$-123M	$-202M
Low	$-14M	$-35M	$-146M	$-233M	$-384M
High	$-9M	$-9M	$-11M	$-47M	$-77M
EBIT Avg	$-12M	$-25M	$-51M	$-123M	$-202M
Low	$-14M	$-35M	$-146M	$-234M	$-385M
High	$-9M	$-9M	$-11M	$-47M	$-77M
Net Income Avg	$-215M	$-286M	$-196M	$-108M	$-25M
Low	$-244M	$-321M	$-253M	$-235M	$-54M
High	$-186M	$-29M	$-138M	$-21M	$-5M
EPS Avg	$-4.81	$-4.77	$-4.04	$-2.42	$-0.56
Low	$-5.44	$-7.17	$-5.66	$-5.26	$-1.21
High	$-4.15	$-0.64	$-3.09	$-0.48	$-0.11
Analysts (Rev / EPS)	4 / 4	5 / 4	6 / 6	4 / 3	3 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$1M	$21M	$2M	$75M	$2M	$5M
Low	$1M	$21M	$2M	$75M	$2M	$5M
High	$1M	$21M	$2M	$75M	$2M	$5M
EBITDA Avg	$-388,340	$-8M	$-613,267	$-29M	$-634,143	$-2M
Low	$-388,340	$-8M	$-613,267	$-29M	$-634,143	$-2M
High	$-388,340	$-8M	$-613,267	$-29M	$-634,143	$-2M
EBIT Avg	$-388,909	$-8M	$-614,167	$-29M	$-635,074	$-2M
Low	$-388,909	$-8M	$-614,167	$-29M	$-635,074	$-2M
High	$-388,909	$-8M	$-614,167	$-29M	$-635,074	$-2M
Net Income Avg	$-81M	$-59M	$-72M	$190M	$-64M	$-63M
Low	$-93M	$-59M	$-72M	$190M	$-64M	$-63M
High	$-70M	$-59M	$-72M	$190M	$-64M	$-63M
EPS Avg	$-1.28	$-0.94	$-1.14	$3.01	$-1.02	$-1.00
Low	$-1.48	$-0.94	$-1.14	$3.01	$-1.02	$-1.00
High	$-1.11	$-0.94	$-1.14	$3.01	$-1.02	$-1.00
Analysts (Rev / EPS)	1 / 2	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 14, 2026Morgan Stanley

Zenas BioPharma price target raised to $32 from $22 at Morgan Stanley

Target:$32.00

+7.2%from $29.84

May 14, 2026Morgan Stanley

Zenas BioPharma price target raised to $22 from $21 at Morgan Stanley

Target:$22.00

+13.2%from $19.43

Jan 6, 2026Jefferies

Zenas Biopharma (ZBIO) PT Lowered to $48 at Jefferies, 'we see clear path for approval (BLA submission planned in 2Q and MAA in 2H26')

Target:$48.00

+189.0%from $16.61

Jan 5, 2026Morgan Stanley

Zenas BioPharma downgraded to Equal Weight from Overweight at Morgan Stanley

Target:$19.00

+14.4%from $16.61

Oct 28, 2025H.C. Wainwright

Zenas BioPharma price target raised to $44 from $30 at H.C. Wainwright

Target:$44.00

+48.3%from $29.67

Oct 27, 2025Morgan Stanley

Zenas Biopharma (ZBIO) PT Raised to $34 at Morgan Stanley

Target:$34.00

+7.4%from $31.65

Oct 27, 2025Jefferies

Zenas Biopharma (ZBIO) PT Raised to $52 at Jefferies

Target:$52.00

+63.5%from $31.80

Oct 8, 2024Jefferies

Zenas BioPharma initiated with a Buy at Jefferies

Target:$35.00

+87.2%from $18.70

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance